Fig. 3

IL13Rα2 depletion delays growth of primary breast tumors. a Representative in vivo bioluminescence images of non-obese diabetic/severe combined immunodeficient mice injected subcutaneously with 5×10⁵ MIV-Luc-shSCR or MIV-Luc-shIL13Rα2#2 cells at different time points post-implantation. b Quantification and comparison of photon flux (photons/sec per cm²) over time (Student’s t test, day 5 P value = 0.96, day 12 P value = 0.0003, day 16 P value = 0.017 and day 22 P value = 0.042, n = 11). *P < 0.05, **P < 0.01, ***P < 0.001. c Comparison of primary tumor weight between MIV-Luc-shSCR and MIV-Luc-shIL13Rα2#2 cell-derived tumors at the experimental endpoint 22 days post-implantation (Student’s t test, P value = 0.0017, n = 15). **P < 0.01. Representative images (d) from hematoxylin and eosin (H&E), anti-IL13Rα2 (brown) and (e) from anti-Ki67 staining (brown) of 10 μm-thick sections from paraffin-embedded primary tumors isolated from mice injected with MIV-Luc-shSCR or MIV-Luc-shIL13Rα2#2 cells (20×). IL13Rα2 interleukin-13 receptor alpha 2, shIL13Rα2 small hairpin RNA against interleukin-13 receptor alpha 2, shSCR scrambled small hairpin RNA